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of the DMM used in this analysis takes into account
results of a regression analysis (pooled glargine versus
NPH clinical trials), which demonstrates a more favour-
able relationship between HbA1c decrease and hypogly-
caemia incidence for glargine versus NPH. Different
cohorts of 10,000 patients with Type 2 diabetes taking
glargine or NPH were assumed. The 3 scenarios tested
differed in target HbA1c attainable by glargine versus
NPH (scenario 1: D = 0.13%; scenario 2: D = 0.44%; sce-
nario 3: D = 0.85%), corresponding to realistic possible
improvements with comparable hypoglycaemia. Assump-
tions were based on clinical trials for scenarios 1 and 2,
and on the regression analysis for scenario 3. RESULTS:
The following relative risks (RR; glargine/NPH) were
obtained for scenarios 1, 2, and 3 respectively: 0.97, 0.89
and 0.81 for long-term microvascular complications
(need for renal dialysis: 0.97, 0.88, and 0.79); 0.99, 0.95,
and 0.91 for long-term macrovascular complications
(non-fatal myocardial infarction: 0.98, 0.95, and 0.88);
0.96, 0.88, and 0.79 for diabetic foot syndrome; and
0.99, 0.94, and 0.90 for mortality. The RR for a noctur-
nal hypoglycaemic event (0.81, 0.92 and 1.01) was con-
sistent with the regression analysis. The RR reductions
ranged from 1% in the less optimistic scenario to >20%
in the “best case” scenario. Varying mean baseline HbA1c
and duration of diabetes in sensitivity analyses did not
alter these outcomes. CONCLUSIONS: Assuming com-
parable hypoglycaemia, the better glycaemic control
(HbA1c reduction) achieved with glargine than with NPH
would lead to reduced long-term complications and mor-
tality rate, based on this model.
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Conﬂicting information exists in the literature regarding
the merit of frequent SMBG to control blood glucose
levels among type 2 diabetics. The American Diabetes
Association (ADA) recommends SMBG to reach and
maintain normal or near-normal glucose levels among
both type 1 and type 2 diabetics. OBJECTIVE: The objec-
tive of this study was to assess whether self-reported
adherence to SMBG was related to HbA1C among type
2 diabetics. METHODS: Type 2 diabetics from a county
family clinic served as the study population. Participants
completed a self-administered survey during seminars
held at the clinic. Chart reviews were conducted to
retrieve baseline (at the time of the seminar) and follow-
up (within one year after the seminar) HbA1C levels, as
well as indication for change in pharmacotherapy. Mul-
tiple regression was used to assess the relationships
between SMBG adherence and HbA1C, while controlling
for demographic (i.e., age, race, and income) and biolog-
ical (i.e., duration of diabetes, comorbidities, change 
in pharmacotherapy, and baseline HbA1C) variables. A
priori signiﬁcance level of .05 was chosen. RESULTS:
Participants (n = 158) were 56.9 (SD: 12.3) years old,
non-white (70.1%), with annual family income between
$20,000 and $30,000, on average. Their adherence to
SMBG was 49.2% (SD: 40.3), which was not associated
with follow-up HbA1C level. Duration of diabetes,
change in pharmacotherapy, and the number of compli-
cations were signiﬁcantly and positively associated with
follow-up HbA1C. CONCLUSIONS: SMBG adherence
was not signiﬁcantly related to follow-up HbA1C among
type 2 diabetics. Maintaining normal or near-normal
blood glucose levels may be more likely associated with
adherence to diet, exercise, and medication. Health prac-
titioners should view SMBG as a tool, rather than a
therapy by itself, and recommend its use to those patients
who can and are willing to act based upon the results.
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OBJECTIVES: To use claims data to estimate the associ-
ation between adherence to medications and clinical out-
comes in DM2 patients. METHODS: Using automated
data from a large health maintenance organization, 
we identiﬁed a sample of 644 patients, age 18 years 
diagnosed with DM2, hypertension, and hyper-
cholesterolemia who receive treatment with either 
cardiovascular or antidiabetic medications between
1999–2001. Patients taking insulin were excluded. We
measured adherence to three classes of drugs, biguanides,
HMG-CoA reductase inhibitors (CoA-I), and ACE-
inhibitors (ACE). Within each drug class, adherence was
measured for those patients who ﬁlled at least one pre-
scription per year. Body mass index and blood pressure
measurements were obtained by medical record ion. Non-
adherence was calculated as a continuous measure of
medication gaps (CMG), which is the proportion of days
without medication during the period of observation. T-
tests or non-parametric tests were used, where appropri-
ate, to compare baseline characteristics and differences in
clinical outcomes. Associations between clinical outcomes
and CMG were estimated using correlation coefﬁcients.
Linear regression models were used to adjust for socio-
demographic and clinical characteristics. RESULTS:
Correlation coefﬁcients were 0.25 for non-adherence 
to biguanides and HbA1c (p < 0.01), 0.32 for non-
adherence to CoA-I and LDL (p < 0.01), and 0.16 for
non-adherence to ACE and SBP (p < 0.01). When com-
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paring adherent patients (1-CMG ≥ 80%) to non-
adherent patients (<80%), mean ± SD levels of HbA1c,
LDL, and BP were lower in the adherent than in the non-
adherent group: 8.0 ± 1.2 vs. 8.5 ± 1.4% for HbA1c 
(p < 0.01), 103.2 ± 28.1 vs. 123.3 ± 34.2mg/dL for LDL
(p < 0.01); and 137.8 ± 12.4 vs. 142.9 ± 12.9mmHg for
SBP (p < 0.01). Adjustment for socio-demographic char-
acteristics did not attenuate the strength of the associa-
tions. CONCLUSIONS: Adherence measured by claims
data correlated with clinical outcomes in DM2 patients.
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OBJECTIVE: To evaluate the impact of a population-
based, diabetes intervention program on patient self-
management behaviors and health system screening 
practices and risk factor management. METHODS:
A population-based diabetes intervention program was
developed by a large, regional managed care plan in the
northern Midwest and a health management subsidiary
of a pharmaceutical company. Program interventions
included periodic education mailings, brochures, newslet-
ters and kits, as well as telephonic case management for
high-risk patients. Six hundred thirty-eight diabetic
members of the health plan completed surveys before and
after one year of program participation, with a 48%
response rate. A second cohort of 956 diabetic patients
that did not participate in the interventions served as a
control group. The evaluation of program impact was
examined using two quasi-experimental designs: 1) one-
group pretest-posttest, and 2) a posttest only design with
nonequivalent groups. Information solicited in the survey
included quality of life issues, frequency of monitoring
activities, behavioral risk factor management, and inter-
mediate clinical outcomes (i.e., HbA1c values, blood pres-
sure, blood glucose levels). RESULTS: Mean quality of
life scores (PAID) improved signiﬁcantly from baseline in
the intervention group (P < 0.01) and were signiﬁcantly
higher than controls (P < 0.01). Statistical improvements
(P < 0.01)were noted from baseline for blood glucose
monitoring. At follow-up, signiﬁcantly more patients in
Cohort 1 reported pre-meal blood glucose levels of <140
(P < 0.01) and mean decreases in low and high blood
sugar episodes. Clinical screening exams were almost all
signiﬁcantly improved in the intervention group com-
pared with controls. With the exception of smoking,
which showed a signiﬁcant decrease in the intervention
group, health behaviors such as following a meal plan
and exercising were not affected. There were no changes
reported in body mass index (BMI). CONCLUSIONS:
A population-based intervention program implemented
within a large health plan produced measurable improve-
ments in diabetes-related behaviors and outcomes.
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OBJECTIVES: Assessing risk proﬁles and medical opti-
misation potentials (MOP) for diabetics participating 
in a German diabetes management (DM) project.
METHODS: Medical record data from privately insured
type-2 diabetics participating in a DM project were used
to calculate individual 10-year-probabilities of com-
plications with a Markov-chain based disease model
(Mellibase). MOPs are the relative risk difference when
comparing present individual risk versus risk of a patient
achieving national guideline values for key risk factors
(HbA1c, systolic blood pressure (SBP), total cholesterol,
HDL cholesterol, triglycerides, smoking status). MOPs
were communicated to patients and their physicians using
Mellibase reports. Assessments are repeated after 3 and
6 months. RESULTS: Of 178 type-2 diabetics (mean 
age 58 years, diabetes diagnosed since median 7 years,
8% females) 97/85% had at least one risk factor at
medium/high level according to guideline. A total of
15/29/28/28% of the diabetics shows 0/1/2/≥3 risk factors
at a high level. A total of 43% of participants exhibit a
MOP for retinopathy of at least 40%. MOPs for myocar-
dial infarction, stroke, foot amputation and renal failure
were 25/15/25/17%. For each 100 DIAMART diabetics
with 1/2/≥3 risk factors at high level the MOPs are equiv-
alent to 5/11/23 less expected events over 10 years,
reﬂecting the enormous opportunity for improvement.
First 3 months follow-up data (80 diabetics) indicate sig-
niﬁcant reductions for HbA1c, SBP, and total cholesterol
among high risk patients. CONCLUSIONS: Diabetics
participating in DIAMART at the start are at high risk
for complications, resulting in substantial MOP. First
follow-up data suggest that MOPs, when used by the
physician via Mellibase reports to inform and motivate
the patient, could be an effective tool to motivate for
reaching recommended guideline risk levels by translat-
ing risk into opportunities. For DM planning MOPs
quantify potential beneﬁts from speciﬁc interventions
(e.g. anti-smoking initiative) in diabetes care and help
focusing efforts on improving outcomes.
